VEGFA and non-small cell lung carcinoma: This study evaluated the efficacy of T-DXd relative to other approved treatments, including immunotherapies, vascular endothelial growth factor inhibitors, and chemotherapies, for adult patients with unresectable locally advanced or metastatic HER2m non-squamous NSCLC whose disease had progressed following ≥1 systemic therapy.<h4>Methods</h4>A systematic literature review was conducted through September 2020 and supplemented in 2023 to identify relevant clinical trials.